• Je něco špatně v tomto záznamu ?

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

M. Buresova, L. Benesova, M. Minarik, R. Ptackova, T. Halkova, P. Hosek, J. Baxa, M. Pesek, M. Svaton, O. Fiala

. 2023 ; 14 (1) : 1-8. [pub] 20230101

Status neindexováno Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003287

Purpose: To investigate potential association between selected tumor markers and laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils, lymphocytes, C-reactive protein, albumin, carcinoembryonic antigen, and cytokeratin 19 fragment 21-1 [CYFRA 21-1]) and circulating tumor DNA (ctDNA) with survival in patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: The study encompassed 82 patients from a single center. All patients had (localy-) advanced adenocarcinomas. ctDNA was determined before starting therapy and at 6 weeks follow-up. Laboratory parameters were measured before each cycle of therapy and oncomarkers before starting the therapy as standard clinical practice. Mann-Whitney U test, Cox proportional hazards model, Fisher's exact test, and Kaplan-Meier survival estimation with Gehan-Wilcoxon test were used for statistical analysis of the corresponding variables. Results: We have confirmed predictive or prognostic significance for some of the selected laboratory markers and oncomarkers. Above all, we demonstrate a significant relationship between the levels of LDH and the oncomarker CYFRA 21-1 and the presence or absence of ctDNA at the time of diagnosis. We also demonstrate significantly lower CRP levels in patients within whom the ctDNA disappeared during treatment. A similar but statistically insignificant trend was observed for LDH. Conclusions: CYFRA 21-1, LDH and probably CRP correlate with ctDNA levels in NSCLC. Repeated measurement of these markers could thus help in early detection of disease progression in the same way as does ctDNA monitoring.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003287
003      
CZ-PrNML
005      
20230421100038.0
007      
ta
008      
230413s2023 at f 000 0|eng||
009      
AR
024    7_
$a 10.7150/jca.78574 $2 doi
035    __
$a (PubMed)36605490
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Buresova, Marcela $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic
245    10
$a Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC / $c M. Buresova, L. Benesova, M. Minarik, R. Ptackova, T. Halkova, P. Hosek, J. Baxa, M. Pesek, M. Svaton, O. Fiala
520    9_
$a Purpose: To investigate potential association between selected tumor markers and laboratory parameters (lactate dehydrogenase [LDH], neutrophils, hemoglobin, neutrophils, lymphocytes, C-reactive protein, albumin, carcinoembryonic antigen, and cytokeratin 19 fragment 21-1 [CYFRA 21-1]) and circulating tumor DNA (ctDNA) with survival in patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: The study encompassed 82 patients from a single center. All patients had (localy-) advanced adenocarcinomas. ctDNA was determined before starting therapy and at 6 weeks follow-up. Laboratory parameters were measured before each cycle of therapy and oncomarkers before starting the therapy as standard clinical practice. Mann-Whitney U test, Cox proportional hazards model, Fisher's exact test, and Kaplan-Meier survival estimation with Gehan-Wilcoxon test were used for statistical analysis of the corresponding variables. Results: We have confirmed predictive or prognostic significance for some of the selected laboratory markers and oncomarkers. Above all, we demonstrate a significant relationship between the levels of LDH and the oncomarker CYFRA 21-1 and the presence or absence of ctDNA at the time of diagnosis. We also demonstrate significantly lower CRP levels in patients within whom the ctDNA disappeared during treatment. A similar but statistically insignificant trend was observed for LDH. Conclusions: CYFRA 21-1, LDH and probably CRP correlate with ctDNA levels in NSCLC. Repeated measurement of these markers could thus help in early detection of disease progression in the same way as does ctDNA monitoring.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benesova, Lucie $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Drnovská 1112/60, Prague, Czech Republic
700    1_
$a Minarik, Marek $u Elphogene, Drnovská 1112/60, Prague, Czech Republic $u Department of Analytical Chemistry, Faculty of Science, Charles University, Hlavova 2030/8, Prague, Czech Republic
700    1_
$a Ptackova, Renata $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Drnovská 1112/60, Prague, Czech Republic
700    1_
$a Halkova, Tereza $u Center for Applied Genomics of Solid Tumors, Genomac Research Institute, Drnovská 1112/60, Prague, Czech Republic
700    1_
$a Hosek, Petr $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, Pilsen, Czech Republic
700    1_
$a Baxa, Jan $u Department of Imaging Methods, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, Pilsen, Czech Republic
700    1_
$a Pesek, Milos $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Fiala, Ondrej $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, alej Svobody 76, Pilsen, Czech Republic $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, alej Svobody 80, Pilsen, Czech Republic
773    0_
$w MED00188770 $t Journal of Cancer $x 1837-9664 $g Roč. 14, č. 1 (2023), s. 1-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36605490 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100030 $b ABA008
999    __
$a ok $b bmc $g 1922851 $s 1189494
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 14 $c 1 $d 1-8 $e 20230101 $i 1837-9664 $m Journal of Cancer $n J Cancer $x MED00188770
LZP    __
$a Pubmed-20230413

Najít záznam

Citační ukazatele

Možnosti archivace